Furthermore, we have demonstrated that ARP-sEVs and CDP-sEVs not only effectively deliver p53 but also significantly inhibit proliferation and induce apoptosis in H1299 lung cancer cells in vitro, with ARP-sEVs exhibiting superior anti-tumor efficacy compared to CDP-sEVs. This evidence concerns the gene TP53 and lung cancer.